First Manhattan’s Crinetics Pharmaceuticals CRNX Stock Holding History

First Manhattan’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-152,200	Closed	-$4.53M	–	1461
2023 Q3	$4.53M	Hold	152,200	–	–	0.02%	224
2023 Q2	$2.74M	Hold	152,200	–	–	0.01%	266
2023 Q1	$2.44M	Hold	152,200	–	–	0.01%	293
2022 Q4	$2.79M	Hold	152,200	–	–	0.01%	296
2022 Q3	$2.99M	Hold	152,200	–	–	0.01%	271
2022 Q2	$2.84M	Hold	152,200	–	–	0.01%	287
2022 Q1	$3.34M	Buy	+152,200	New	+$3.08M	0.01%	296
2019 Q3	–	Sell	-188	Closed	-$4K	–	1338
2019 Q2	$4K	Hold	188	–	–	﹤0.01%	1257
2019 Q1	$4K	Buy	+188	New	+$4.62K	﹤0.01%	1282

Other funds holding CRNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

First Manhattan's CRNX Position: Q4 2023 in Review

First Manhattan sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2023, closing a stake of 152,200 shares — an estimated $4.53M sold.

First Manhattan first reported a position in CRNX in Q1 2019 and held it in 9 quarters. The position peaked at $4.53M in Q3 2023. 181 funds tracked by Wall St. Rank hold CRNX as of Q4 2023.

First Manhattan reported no remaining Crinetics Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 152,200 Crinetics Pharmaceuticals shares in Q4 2023, an estimated $4.53M.
First Manhattan first reported a position in Crinetics Pharmaceuticals in Q1 2019 and held it in 9 quarters.
First Manhattan's Crinetics Pharmaceuticals position peaked at $4.53M in Q3 2023.
181 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.